Abstract Increased risk of arterial and venous thromboembolic disease is well documented in tbe homocystinuric patient. Therc is growing evidence that hyperhomocysteinemia is an independent risk factor for premature arteriosclerotic disease, including cerebral, peripheral, and coronary vascular diseases. So far no association has been established between hyperhomogateinemia and venous thromboembolism.We studied 35 pa_tients,-young adults (age less than 56 years) with venographically and/or ultrasonographically verified deep venous lhrombosis (DW). Patients with coexisting diseases were excluded. t32l homocystinuria. Vascular episodes may occur in early adolescence and even in childhood.''2
t32l
homocystinuria. Vascular episodes may occur in early adolescence and even in childhood.' '2 Homorystinuria denotes a clas of disease characterized by impaired homocysteine metabolism that leads to marked elevation of the homocysteine level in the blood and massive urinary excretion of homocystine.r The fact that early vascular disease is observed in homocystinuria caused by different enzymatic defects suggests that homocysteine itself may be responsible for the vascular Iesions.
Moderate hyperhomocysteinemia is common in the general population and is caused by both genetic and acquired conditions, including folate and-cobalamin deficiency.3 Approximately 25 retrospective studies based on approximately 2500 patients and a comparable number of dontrol subjectsrc and two recent prospective investigationsT'8 have demonstrated that hyperhomocysteinemia is an independent risk factor for premature arteriosclerotic disease in the coronary, cerlbral, and peripheral arteries. The condition can often be corrected with an oral vitamin supplement that is simple and inexpensive.e VTE, including DVT and PE, accounts for at least 50Vo of the vascular events in homocystinuria.t,to However, only three reportS on hyperhomogrsteinemia and venous thrombosis have been published, and the results are conflicting. Brattstrcim et alrt found no significant difference in plasma homocysteine concentrations between 42 patients with VTE and healthy control subjects, although the male patients showed a tendency The present study addresses whether hyperhomocysteinemia may predispose to venous thrombosis in addition to arteriosclerotic disease. We measured plasma homocysteine during fasting and after methioninl loading in 34 patients presenting with DYT before the age of 56 years.
Methods

Patients
Adults less than 56 years of age at the time of diagnosis who had venographically and/or ulrrasonographically verified DVT of the lower extremities and had been hospitalized over a 4-year period, from 1988 through 1991, in the Department of Medicine at University Hospital, Trondheim, were included. Patients hospitalized from 1988 through 1989 were studied retrospectively, and patients hospitalized from 1990 through 1991 were included consecutivelv.
Exclusion criteria included pitients with diabetes mellitus; patients with kidney, liver, or thyroid diseases; patients receiving lipid-lowering agents; patients receiving nitrous oxide within 3 months of onset of DVT; patients with acute or severe illness requiring immobilization in bed; and patients with malignant diseases. Secondary causes of exclusion (1 patient each, unless indicated othenvise) in this study wera ejsential thrombocythemia and cerebrovascular disease, ulcerative colitis, hypertension and cesarean section less than I month before the onset of DW, purulent meningitis and purulent arthritis, ovarian cancer and cerebrovascular disease, oligophrenia and epilepsy, chronic alcoholism, chronic renal failure (3 patients), and recunent DVT at the time of inclusion (2 patients). In addition, death (4 patients), living too far away from the hospital (2 patients), and lack of conscnt (18 patients) were causes of exclusion. Altogether, 37 of.72 patients were excluded.
The remaining patients comprised 17 women (mean age, 41.5 years; range, 21 to 56 yean) and 18 men (mean age, z165 years; range, 20 to 56 years), including postoperative DVT (3 patients), posttraumatic DVT (3 patients), and protein S Selected Abbreviations and Acronyms DVT = decp vcnous thrombosis PCG = cysteinylglycine PQ6 = grsteine PE = pulmonary cmbolism PHq, = plasmahomocystcine ' VIE = vcnous thromboembolism deficiency (1 patient). All patients and control subjects were screened for protein C-, protein S-, and antithrombin III deficiency.
As control subjects 39 healthy blood donors were matched to the patient group for age and sex (19 women
A methionine loading test was performed by oral administration of methionine (100 mg/kg body wt) in 200 mL of orange juice after overnight fasting. Patients and control subjects had no extra vitamin intake during the week before the loading test. Blood samples were collected immediately before the methionine intake (8 rult) and after 6 hours, centrifuged, and stored at -70'C until they were assayed at the same time. Total PHC.!, PCls, and PCG were measured by high-performance liquid chromatography; details of these assays are provided elsewhere.la
The Mann-Whitney test rvas used to compare the PHCy, PC,!s, and PCG concentrations between patients and control subjects. A value of P<.05 was considered significant. The results are expressed as meantSD.
Results
PHCy preloading values for patients rvere 10.3+3.5 p,mol/L and for control subjects 10.3-'-2.6 F,mol/L (Figure) . PHCy postloading values for patients were 39.51'14.2 g.mol/L and for control subjects 37.2-r74.2 pmol/L (Figure) . Two (5.7%) of the 35 patients and 1 (2.6Vo) of the 39 control subjects had PHC.! values 2 SD above mean values for both preloading and postloading values. The control subject with a markedly elevated postloading value was retested after 11 months and at that time had normal PHCy levels. Logarithmic PHCy preloading and Coitrolt Vol 15, No 9 September 1995 postloading values in each group were compared and showed no significant difference (P>.1).
PCls preloading values for patients were 249.7+30-7 trr.moVl-and for control subjects were 256.9!32.1 F,moVL. PQ6 postloading values for patients were 230.7'+32.9 pmol/L and for control subjects 242.11-27-B pmovL.
PCG preloading values for patients rvere 29.2-14.8 pmoUl-and for control subjects 28.4'F4.6 rrmolll PCG postloading values for patients were 22.8l-4.4 pnoW and for controls 2t.1+39 pmofiL.
There was no significant difference between patients and control subjects for PHC), PCls, and PCG concentrations for preloading and postloading values and for the difference between the preloading and postloading values.
Serum Bl2levels for patients were289.2!94.7 nmoW and for control subjects 325.1-F103.9 nmol/T. (P=.127). Serum folate values for patients were 12.8-r4.3 nmol/L and for control subjects 14.49'+-5.4 nmolll (P:.1a4).
Discussion
We found no significant difference in preload and postload PHC) between 35 patients with DVT (28 without knorvn cause) occurring before the age of56 years and 39 sex-and age-matched control subjects. The mean fasting PHCy concentration in both patients and control subjects (:10.3 rrmol/I, the Figure) equaled the levels previously found in 3000 healthy men aged 40 to 42 years. 3 AJthough the number of patients is small, our data show that hyperhomocysteinemia and abnormal homocysteine responses to a standard methionine load are not important risk factors for DVT. Our results are in agreement rvith those of Brattstrom et alrr who found no significant difference in fasting and postload plasma homocysteine levels benveen 42 patients with D\T and 42 healthy control subjects. Most of their patients had no predisposing disease or risk factor for thrombosis.
In contrast, Bienvenu et alr2 reported that 7 of 23 patients with V'fE had significantly increased (>2 SD) fasting PHC) levels and concluded that hyperhomocysteinemia is a risk factor for venous and arterial thromboses. However, the subjects with VTE studied by Bienvenu et al included patients with pulmonary embolism, Budd-Chiari syndrome, central vein occlusion, and mesenterial vein thrombosis, in addition to DVT; some patients also had coexisting disease often associated with VTE. The mean age of the patient group (40 years; range, tl to 57 years) seemed to be higher than that of the control group (33 years; range, 18 to 50 yean). Finally, they used the Student's t test to compare PHCy levels, which are known to be not normally distribut6d.r2"rs Thus, the design of this study makes it difrcult to evaluate hyperhomocysteinemia as an isolated risk factor for DVT, and therefore to compare their study to the current study.
The study of Falcon et alr3 on the other hand shorvs that the postload increment of homocysteine but not the fasting level was significantly higher in patients with VTE before the age of 40 years compared with age-and sex-matched controls. They studied patients with VTE referred to a center for juvenile venous thrombosis (mean age,33 years). More than SOVI of.the patients had two or more episodes of VTE, and 48Vo-of. the episodes occurred in pregnant women or in women taking oral Plasma.homocysteine levels in patients before and after intake (preloading .and tively) of methionine. contraceptives. AII the hyperhomocysteinemic patients had two or more episodes of VTE. Therefore, the study of Falcon et al represents a more selected group of patients (v_ery_loung patients with recurrent VTE) Compared with those in our study. Nearly 50Vo of. the hyperhomoqrsteinemic patienrs (7 of 15 patients) had a positive family history of VTE, and 50Vo of these shorved inherited abnormality. The prevalence of hyperhomocysteinemia in the general population is estimated to be approximately 1Vo, although it may vary from area to area-t In a nonseiected DVT population, hyperhomocysteinemia as an independent risk factor probably would be diluted, and-the association may not reach significant levels. Twentyeight of the 35 patients in our study had DVT without known cause, and the remaining 7 patients had postoperative and posttraumatic DVT (3 patients each) and protein S deficiency (1 patient). Despite this selection, hyperhomorysteinemia as a possible risk factor may be underestimated in our study because of the small number of patients (type II error).
In conclusion, only three clinical studies, which included a limited number of patients, have analyzed hyperhomocysteinemia as a possible risk factor for VTE. The current study and one Swedish studyrr failed to demonstrate such a relation, whereas two other 5tudis5t2"t: suggest a high prevalence of hyperhomocysteinemia in young patients rvith VTE. However, the studies are not directly comparable, and the problem is still unresolved. Hyperhomocysteinemia possibly predisposes to early-onset VTE, but its association with VTE is weaker than with premature arteriosclerosis. The combination of hyperhomocysteinemia and VTE may reflect an inherited abnormality,rr and this relation may be more pronounced in certain ethnic groups and in younger patients rvith recurrent DVT. Further studies are recommended before the clinical value of plasmahomocysteine screening can be determined in patients with VTE.
Note added in proof,ln a newly published article by den Heijer et al, they concluded that hyperhomocysteinemia is a common risk factor for recurrent venous thrombosis. This is in agreement with our final suggestions. 16 
